Literature DB >> 25529089

Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.

Joy Peter1, David R Nelson.   

Abstract

Over the past year, interferon (IFN) free dosing regimens have become available to treat chronic hepatitis C. Offering high rates of sustained virological response (SVR), short treatment and improved tolerability, IFN-free treatment now represents the paradigm for both treatment-naïve and -experienced patients. Patients with prior treatment failure, in particular those with cirrhosis, still represent some of the most difficult to treat, but the availability of multiple agents that can interrupt several steps of the HCV lifecycle affords providers and patients with options that can be combined and individually tailored to each patient's unique needs to obtain high rates of SVR.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  direct acting antivirals; hepatitis C; treatment

Mesh:

Substances:

Year:  2015        PMID: 25529089     DOI: 10.1111/liv.12718

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  9 in total

Review 1.  Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.

Authors:  Sarah Talavera Pons; Anne Boyer; Geraldine Lamblin; Philip Chennell; François-Thibault Châtenet; Carine Nicolas; Valérie Sautou; Armand Abergel
Journal:  Br J Clin Pharmacol       Date:  2016-10-26       Impact factor: 4.335

Review 2.  New treatment strategies for hepatitis C infection.

Authors:  Fatih Ermis; Elif Senocak Tasci
Journal:  World J Hepatol       Date:  2015-08-18

Review 3.  Hepatitis C genotype 4: The past, present, and future.

Authors:  Tawhida Y Abdel-Ghaffar; Mostafa M Sira; Suzan El Naghi
Journal:  World J Hepatol       Date:  2015-12-08

Review 4.  Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2015-06       Impact factor: 11.431

5.  Grape Seed Extract Attenuates Hepatitis C Virus Replication and Virus-Induced Inflammation.

Authors:  Wei-Chun Chen; Chin-Kai Tseng; Bing-Hung Chen; Chun-Kuang Lin; Jin-Ching Lee
Journal:  Front Pharmacol       Date:  2016-12-21       Impact factor: 5.810

6.  Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.

Authors:  Stevan A Gonzalez; Daniel S Fierer; Andrew H Talal
Journal:  Addict Disord Their Treat       Date:  2017-05-17

7.  Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C.

Authors:  Camelia Sultana; Gabriela Oprişan; Monica Delia Teleman; Sorin Dinu; Cristiana Oprea; Mihai Voiculescu; Simona Ruta
Journal:  World J Gastroenterol       Date:  2016-10-07       Impact factor: 5.742

8.  Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.

Authors:  Prajakta S Badri; Sandeep Dutta; Haoyu Wang; Thomas J Podsadecki; Akshanth R Polepally; Amit Khatri; Jiuhong Zha; Yi-Lin Chiu; Walid M Awni; Rajeev M Menon
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

Review 9.  The new era of hepatitis C virus therapy.

Authors:  Bandar Al-Judaibi
Journal:  Saudi J Gastroenterol       Date:  2015 Nov-Dec       Impact factor: 2.485

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.